CAJ | 학술논문

4～6周期联合化疗达到"化疗疗效平台"后,进一步维持治疗能否改善进展期非小细胞肺癌患者的生存,是目前临床关注的热点.随着一些具有良好耐受性的化疗药物和分子靶向药物的介入,一些临床研究已经证实,在疾病控制的患者,维持治疗能带来进一步的临床获益,主要表现为无进展生存期的延长,并有改善总生存的趋势.
4～6주기연합화료체도"화료료효평태"후,진일보유지치료능부개선진전기비소세포폐암환자적생존,시목전림상관주적열점.수착일사구유량호내수성적화료약물화분자파향약물적개입,일사림상연구이경증실,재질병공제적환자,유지치료능대래진일보적림상획익,주요표현위무진전생존기적연장,병유개선총생존적추세.
Following four to six cycles of chemotherapy for patients with non-small cell lung cancer　( NSCLC). Chemotherapy efficacy plateau has been achieved. Whether maintenance therapy can improve these patient' s survival becomes a new focus now. Several randomized clinical trials have demonstrated that mainte-nance therapy with well-tolerated chemotherapeutic or molecular-targeted agents may benefit patients with ad-vanced NSCLC who experience a response or disease stabilization after chemotherapy, which include prolonging progression-free survival and attering total survival.